Skip Nav Destination
Issues
1 April 2007
-
Cover Image
Cover Image
Immunohistochemistry of a glioblastoma tumor specimen with monoclonal antibodies specific for the mismatch repair protein MSH6. Loss of MSH6 is found in recurrent glioblastomas and is associated with the progressive growth of these tumors while they are under treatment with the alkylating chemotherapeutic agent temozolomide. Because mismatch repair deficiency is known to mediate alkylator drug resistance in vitro, and temozolomide is a component of the standard-of-care treatment for glioblastoma, the finding of MSH6 loss in glioblastoma recurrences links the well-established in vitro phenomenon to the most common clinical treatment scenario encountered in the care of neuro-oncology patients. For further details, please see Cahill et al. on page 2038 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
Molecular Pathways
Review
Human Cancer Biology
3q26 Amplification and Polysomy of Chromosome 3 in Squamous Cell Lesions of the Lung: A Fluorescence In situ Hybridization Study
Giuseppe Pelosi; Barbara Del Curto; Maurizio Trubia; Andrew G. Nicholson; Michela Manzotti; Giulia Veronesi; Lorenzo Spaggiari; Patrick Maisonneuve; Felice Pasini; Alberto Terzi; Antonio Iannucci; Giuseppe Viale
Imaging, Diagnosis, Prognosis
Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer
David R. Shaffer; Margaret A. Leversha; Daniel C. Danila; Oscar Lin; Rita Gonzalez-Espinoza; Bin Gu; Aseem Anand; Katherine Smith; Peter Maslak; Gerald V. Doyle; Leon W.M.M. Terstappen; Hans Lilja; Glenn Heller; Martin Fleisher; Howard I. Scher
Adrenal Androgen Levels as Predictors of Outcome in Prostate Cancer Patients Treated with Ketoconazole Plus Antiandrogen Withdrawal: Results from a Cancer and Leukemia Group B Study
Charles J. Ryan; Susan Halabi; San-San Ou; Nicholas J. Vogelzang; Philip Kantoff; Eric J. Small; for the Cancer and Leukemia Group B
Loss of the Mismatch Repair Protein MSH6 in Human Glioblastomas Is Associated with Tumor Progression during Temozolomide Treatment
Daniel P. Cahill; Kymberly K. Levine; Rebecca A. Betensky; Patrick J. Codd; Candice A. Romany; Linsey B. Reavie; Tracy T. Batchelor; P. Andrew Futreal; Michael R. Stratton; William T. Curry; A. John Iafrate; David N. Louis
Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer
Fabrice Andre; Christos Hatzis; Keith Anderson; Christos Sotiriou; Chafika Mazouni; Jaime Mejia; Bailiang Wang; Gabriel N. Hortobagyi; W. Fraser Symmans; Lajos Pusztai
Tumor-Infiltrating Foxp3−CD4+CD25+ T Cells Predict Poor Survival in Renal Cell Carcinoma
Sameer A. Siddiqui; Xavier Frigola; Sandra Bonne-Annee; Maria Mercader; Susan M. Kuntz; Amy E. Krambeck; Shomik Sengupta; Haidong Dong; John C. Cheville; Christine M. Lohse; Christopher J. Krco; W. Scott Webster; Bradley C. Leibovich; Michael L. Blute; Keith L. Knutson; Eugene D. Kwon
Cancer Therapy: Clinical
A Phase I Pharmacokinetic and Pharmacodynamic Study of S-3304, a Novel Matrix Metalloproteinase Inhibitor, in Patients with Advanced and Refractory Solid Tumors
Alberto A. Chiappori; S. Gail Eckhardt; Ronald Bukowski; Daniel M. Sullivan; Minoru Ikeda; Yoshitaka Yano; Takuko Yamada-Sawada; Yoshikaze Kambayashi; Kazushige Tanaka; Milind M. Javle; Tarek Mekhail; Cindy L. O'Bryant; Patrick J. Creaven
Effects of the Administration of High-Dose Interleukin-2 on Immunoregulatory Cell Subsets in Patients with Advanced Melanoma and Renal Cell Cancer
Hans J.J. van derVliet; Henry B. Koon; Simon C. Yue; Burak Uzunparmak; Virginia Seery; Marc A. Gavin; Alexander Y. Rudensky; Michael B. Atkins; Steven P. Balk; Mark A. Exley
A Phase I Pharmacokinetic and Pharmacodynamic Study of PX-12, a Novel Inhibitor of Thioredoxin-1, in Patients with Advanced Solid Tumors
Ramesh K. Ramanathan; D. Lynn Kirkpatrick; Chandra P. Belani; David Friedland; Sylvan B. Green; H-H. Sherry Chow; Catherine A. Cordova; Steven P. Stratton; Elizabeth R. Sharlow; Amanda Baker; Tomislav Dragovich
Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors
Julie L. Eiseman; Jianxia Guo; Ramesh K. Ramanathan; Chandra P. Belani; David B. Solit; Howard I. Scher; S. Percy Ivy; Eleanor G. Zuhowski; Merrill J. Egorin
Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors
Saifee A. Mullamitha; Nhuan C. Ton; Geoff J.M. Parker; Alan Jackson; Peter J. Julyan; Caleb Roberts; Gio A. Buonaccorsi; Yvonne Watson; Karen Davies; Sue Cheung; Lynn Hope; Juan W. Valle; John A. Radford; Jeremy Lawrance; Mark P. Saunders; Mihaela C. Munteanu; Marian T. Nakada; Jeffrey A. Nemeth; Hugh M. Davis; Qun Jiao; Uma Prabhakar; Zhihui Lang; Robert E. Corringham; Robert A. Beckman; Gordon C. Jayson; in association with the Biotherapy Development Association
Cancer Therapy: Preclinical
Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity
Syed-Rehan A. Hussain; Carolyn M. Cheney; Amy J. Johnson; Thomas S. Lin; Michael R. Grever; Michael A. Caligiuri; David M. Lucas; John C. Byrd
Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer
Takeo Nomi; Masayuki Sho; Takahiro Akahori; Kaoru Hamada; Atsushi Kubo; Hiromichi Kanehiro; Shinji Nakamura; Koji Enomoto; Hideo Yagita; Miyuki Azuma; Yoshiyuki Nakajima
Systemic CTLA-4 Blockade Ameliorates Glioma-Induced Changes to the CD4+ T Cell Compartment without Affecting Regulatory T-Cell Function
Peter E. Fecci; Hidenobu Ochiai; Duane A. Mitchell; Peter M. Grossi; Alison E. Sweeney; Gary E. Archer; Thomas Cummings; James P. Allison; Darell D. Bigner; John H. Sampson
Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models
Lyuba Varticovski; Melinda G. Hollingshead; Ana I. Robles; Xiaolin Wu; James Cherry; David J. Munroe; Luanne Lukes; Miriam R. Anver; John P. Carter; Suzanne D. Borgel; Howard Stotler; Carrie A. Bonomi; Nomelí P. Nunez; Stephen D. Hursting; Wenhui Qiao; Chuxia X. Deng; Jeff E. Green; Kent W. Hunter; Glenn Merlino; Patricia S. Steeg; Lalage M. Wakefield; J. Carl Barrett
Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1
Ramzi M. Mohammad; Anton Scott Goustin; Amro Aboukameel; Ben Chen; Sanjeev Banerjee; Guoping Wang; Zaneta Nikolovska-Coleska; Shaomeng Wang; Ayad Al-Katib
Menatetrenone, a Vitamin K2 Analogue, Inhibits Hepatocellular Carcinoma Cell Growth by Suppressing Cyclin D1 Expression through Inhibition of Nuclear Factor κB Activation
Iwata Ozaki; Hao Zhang; Toshihiko Mizuta; Yasushi Ide; Yuichiro Eguchi; Tsutomu Yasutake; Toshiyuki Sakamaki; Richard G. Pestell; Kyosuke Yamamoto
Cancer Prevention
Identification of a Highly Effective Rapamycin Schedule that Markedly Reduces the Size, Multiplicity, and Phenotypic Progression of Tobacco Carcinogen–Induced Murine Lung Tumors
Courtney A. Granville; Noel Warfel; Junji Tsurutani; M. Christine Hollander; Matthew Robertson; Stephen D. Fox; Timothy D. Veenstra; Haleem J. Issaq; R. Ilona Linnoila; Phillip A. Dennis
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.